Abstract: Disclosed is a liquid composition of human albumin for therapeutic use, in which at least 50% of the albumin has a molecular weight of 66.438 Da, plus or minus 5 Da, preferentially plus or minus 2 Da, the composition also including a sodium salt.

Abstract: An anti-Factor VII affinity ligand that is particularly useful for purifying recombinant human activated Factor VII from transgenic sources. The affinity ligand combined with other orthogonal chromatographic steps allows the preparation of a highly purified FVII solution fully activated free of aggregates with a low percentage of degraded or oxidized FVII forms.

Abstract: An affinity substrate for the selective binding of a protein of blood plasma includes a solid substrate material on which are immobilized deoxyribonucleic aptamers specifically binding with the plasma protein.

Abstract: Process for separating proteins fibrinogen, Factor XIII and biological glue from a solubilized plasma fraction and for preparing lyophilized concentrates of said proteins.

Abstract: Process for separating proteins fibrinogen, Factor XIII and biological glue from a solubilized plasma fraction and for preparing lyophilized concentrates of said proteins.

Abstract: An anti-Factor VII affinity ligand that is particularly useful for purifying recombinant human activated Factor VII from transgenic sources. The affinity ligand combined with other orthogonal chromatographic steps allows the preparation of a highly purified FVII solution fully activated free of aggregates with a low percentage of degraded or oxidized FVII forms.

Abstract: Process for separating proteins fibrinogen, Factor XIII and biological glue from a solubilized plasma fraction and for preparing lyophilised concentrates of said proteins.

Abstract: Process for separating proteins fibrinogen, Factor XIII and biological glue from a solubilized plasma fraction and for preparing lyophilised concentrates of said proteins.

Abstract: The invention relates to a method for extracting a protein from milk, having at least one hydrophobic pocket and a negative charge to the natural pH of milk, that comprises the following steps: a) skimming and delipidation of the milk; b) passing the delipidated and skimmed fraction containing the protein on a chromatographic substrate on which is grafted a ligand having both a hydrophobic characteristic and an ionic characteristic in pH conditions enabling the protein to be retained on the substrate, the pH being higher than 4.6; c) elution of the protein; d) purification of the eluted fraction by removing the milk proteins from the eluted fraction; and e) recovering the protein.

Abstract: The invention relates to a method for extracting a protein from milk, having at least one hydrophobic pocket and a negative charge to the natural pH of milk, that comprises the following steps: a) skimming and delipidation of the milk; b) passing the delipidated and skimmed fraction containing the protein on a chromatographic substrate on which is grafted a ligand having both a hydrophobic characteristic and an ionic characteristic in pH conditions enabling the protein to be retained on the substrate, the pH being higher than 4.6; c) elution of the protein; d) purification of the eluted fraction by removing the milk proteins from the eluted fraction; and e) recovering the protein.

Abstract: An affinity substrate for the selective binding of a protein of blood plasma includes a solid substrate material on which are immobilized deoxyribonucleic aptamers specifically binding with the plasma protein.

Abstract: An affinity substrate for selectively binding a coagulation protein, includes a substrate solid on which nucleic aptamers binding specifically to the coagulation protein are immobilized.

Abstract: La present invention pertains to a composition of plasma-derived virally-safe factor VIII, obtained after nanometric filtration, said composition comprising von Willebrand factor (vWF) at a rate of 15% or less of decamers and higher multimers. Such compositions have a reduction factor of the virus titre higher than 4 log and are thus suitable for treatment of hemophilia.

Abstract: The invention is related to a process for extracting at least one protein present in milk, said protein exhibiting an affinity for the complexed or non-complexed calcium ions of said milk, comprising the following steps consisting of: a) releasing the protein by precipitation of calcium compounds obtained by contacting the milk with a soluble salt, the anion of which is selected for its capability to form said insoluble calcium compounds in such a medium, in order to obtain in this way a protein-enriched liquid phase, b) separating the protein-enriched liquid phase from the precipitate of calcium compounds, said liquid phase being, moreover, separated in a lipidic phase and in a non-lipidic aqueous phase comprising the protein, and c) recovering the non-lipidic aqueous phase comprising the protein.

Abstract: The invention relates to a method for extracting a protein from milk, having at least one hydrophobic pocket and a negative charge to the natural pH of milk, that comprises the following steps: a) skimming and delipidation of the milk; b) passing the delipidated and skimmed fraction containing said protein on a chromatographic substrate on which is grafted a ligand having both a hydrophobic characteristic and a ionic characteristic in pH conditions enabling the protein to be retained on said substrate, the pH being higher than 4.6; c) elution of the protein; d) purification of the eluded fraction by removing the milk proteins from said eluded fraction; and e) recovering said protein.

Abstract: La present invention pertains to a composition of plasma-derived virally-safe factor VIII, obtained after nanometric filtration, said composition comprising von Willebrand factor (vWF) at a rate of 15% or less of decamers and higher multimers. Such compositions have a reduction factor of the virus titre higher than 4 log and are thus suitable for treatment of hemophilia.

Abstract: Method for preparing a factor VIII solution that is essentially free of viruses and essentially devoid of vWF (von Willebrand factor) and factor VIII-vWF complexes by (a) obtaining a starting factor VIII solution devoid of factor VIII-vWF complexes; and (b) filtering the solution through a hydrophilic virus filter.